Prescription drug · NDA
Pluvicto (lutetium lu 177 vipivotide tetraxetan) NDC 0078-1217
Lutetium lu-177 vipivotide tetraxetan 27 mCi/mL · Injection, Solution · Intravenous · Novartis Pharmaceuticals Corporation
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 0078-1217-61 | 00078121761 | 1 VIAL, GLASS in 1 PACKAGE (0078-1217-61) / 7.5 mL in 1 VIAL, GLASSMarketed from Jan 15, 2026 |
How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Pluvicto
- Generic name (nonproprietary)
- lutetium lu 177 vipivotide tetraxetan
- Active ingredients
- Lutetium lu-177 vipivotide tetraxetan — 27 mCi/mL
- Dosage form
- Injection, Solution
- Route
- Intravenous
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 215833
- Marketing start
- Listing expires
- Other FDA classes
- Radioligand Activity (Mechanism)
- Identifiers
- Product ID 0078-1217_ade5aa80-b303-470f-8e79-7edea0c4a1bcSPL ID ade5aa80-b303-470f-8e79-7edea0c4a1bcSPL set ID 14908037-2892-4d98-a053-253ce35afb1aRxCUI 2597057, 2597060UNII G6UF363ECX
- Pharmacologic class
- Radioligand Therapeutic Agent
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N400078121761followed by a unit qualifier and the quantityPackage 00078-1217-61. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
PLUVICTO is a radioligand therapeutic agent indicated: Metastatic Androgen Pathway Modulation-Naïve or -Sensitive (mAPMN/S) Prostate Cancer in combination with androgen receptor pathway inhibitor (ARPI) therapy for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer. ( 1.1 ) Metastatic Androgen Pathway Modulation-Resistant (mAPMR) Prostate Cancer for the treatment of adult patients with PSMA-positive metastatic androgen pathway modulation-resistant (mAPMR) prostate cancer who have been treated with ARPI therapy, and are considered appropriate to delay taxane-based chemothe…
Excerpt only. Read the full label for complete information.